Preclinical studies in rats and squirrel monkeys for safety evaluation of the bivalent anti-human T cell immunotoxin, A-dmDT390-bisFv(UCHT1)

Cancer Immunology, Immunotherapy

Volumn 57, Issue 8, 2008, Pages 1225-1239

  Woo, Jung Hee ^a   Bour, Sarah H ^a   Dang, Tony ^a,c   Lee, Yu Jen ^a   Park, Seong Kyu ^a   Andreas, Elissa ^a   Kang, Soo Hyun ^a   Liu, Jen Sing ^a   Neville Jr , David M ^b   Frankel, Arthur E ^a  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^c Pharmaceutical Sciences   (United States)

Author keywords

CD3 positive; Diphtheria toxin; MTD; UCHT1

Indexed keywords

AMINOTRANSFERASE; CD3 ANTIGEN; DIPHTHERIA TOXIN; IMMUNOTOXIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANIMAL EXPERIMENT; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD SAMPLING; CLINICAL STUDY; CYTOKINE RELEASE; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; LETHARGY; MALE; MAXIMUM TOLERATED DOSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMA HALF LIFE; PRIORITY JOURNAL; RAT; SAFETY; SIDE EFFECT; SQUIRREL MONKEY; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TOXICOLOGY; WEIGHT REDUCTION;

ADULT; ANIMALS; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; DRUG TOXICITY; FEMALE; HUMANS; IMMUNOTOXINS; LEUKOCYTES, MONONUCLEAR; MALE; MAXIMUM TOLERATED DOSE; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT FUSION PROTEINS; SAIMIRI; T-LYMPHOCYTES;

EID: 44249122848     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-008-0457-x     Document Type: Article

References (54)

1. The Non-Hodgkin's Lymphoma Classification Project (1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 89:3909-3918
2. Yokote T, Akioka T, Oka S, Hara S, Kobayashi K, Nakajima H, Yamano T, Ikemoto T, Shimizu A, Tsuji M, Hanafusa T (2005) Flow cytometric immunophenotyping of adult T-cell leukemia/lymphoma using CD3 gating. Am J Clin Pathol 124:199-204
3. Suzushima H, Asou N, Nishimura S, Nishikawa K, Wang JX, Okubo T, Naito M, Hattori T, Takatsuki K (1993) Double-negative (CD4- CD8-) T cells from adult T-cell leukemia patients also have poor expression of the T-cell receptor alpha beta/CD3 complex. Blood 81:1032-1039
4. Sandberg Y, Almeida J, Gonzalez M, Lima M, Barcena P, Szczepanski T, van Gastel-Mol EJ, Wind H, Balanzategui A, van Dongen JJ, Miguel JF, Orfao A, Langerak AW (2006) TCRgammadelta+ large granular lymphocyte leukemias reflect the spectrum of normal antigen-selected TCRgammadelta+ T-cells. Leukemia 20:505-513
5. Gentile TC, Uner AH, Hutchison RE, Wright J, Ben-Ezra J, Russell EC, Loughran TP Jr (1994) CD3+, CD56+ aggressive variant of large granular lymphocyte leukemia. Blood 84:2315-2321
6. Bakrac M, Bonaci B, Krstic M, Simic S, Colovic M (2006) A rare case of enteropathy-associated T-cell lymphoma presenting as acute renal failure. World J Gastroenterol 12:2301-2304
7. de Bruin PC, Connolly CE, Oudejans JJ, Kummer JA, Jansen W, McCarthy CF, Meijer CJ (1997) Enteropathy-associated T-cell lymphomas have a cytotoxic T-cell phenotype. Histopathology 31:313-317
8. Salhany KE, Feldman M, Kahn MJ, Peritt D, Schretzenmair RD, Wilson DM, DiPaola RS, Glick AD, Kant JA, Nowell PC, Kamoun M (1997) Hepatosplenic gammadelta T-cell lymphoma: ultrastructural, immunophenotypic, and functional evidence for cytotoxic T lymphocyte differentiation. Hum Pathol 28:674-685
9. Baseggio L, Berger F, Monneret G, Magaud JP, Salles G, Felman P (2006) The expression of TCR-gamma delta/CD3 complex in neoplastic gamma delta T-cell. Haematologica 91:1717-1719
10. Wu H, Wasik MA, Przybylski G, Finan J, Haynes B, Moore H, Leonard DG, Montone KT, Naji A, Nowell PC, Kamoun M, Tomaszewski JE, Salhany KE (2000) Hepatosplenic gamma-delta T-cell lymphoma as a late-onset posttransplant lymphoproliferative disorder in renal transplant recipients. Am J Clin Pathol 113:487-96
11. Kraus MD, Crawford DF, Kaleem Z, Shenoy S, MacArthur CA, Longtine JA (1998) T gamma/delta hepatosplenic lymphoma in a heart transplant patient after an Epstein-Barr virus positive lymphoproliferative disorder: a case report. Cancer 82:983-992
12. Steurer M, Stauder R, Grunewald K, Gunsilius E, Duba HC, Gastl G, Dirnhofer S (2002) Hepatosplenic gammadelta-T-cell lymphoma with leukemic course after renal transplantation. Hum Pathol 33:253-258
13. Francois A, Lesesve JF, Stamatoullas A, Comoz F, Lenormand B, Etienne I, Mendel I, Hemet J, Bastard C, Tilly H (1997) Hepatosplenic gamma/delta T-cell lymphoma: a report of two cases in immunocompromised patients, associated with isochromosome 7q. Am J Surg Pathol 21:781-790
14. Washington LT, Huh YO, Powers LC, Duvic M, Jones D (2002) A stable aberrant immunophenotype characterizes nearly all cases of cutaneous T-cell lymphoma in blood and can be used to monitor response to therapy. BMC Clin Pathol 2:5
15. Chott A, Dragosics B, Radaszkiewicz T (1992) Peripheral T-cell lymphomas of the intestine. Am J Pathol 141:1361-1371
16. Al Shanqeety O, Mourad WA (2000) Diagnosis of peripheral T-cell lymphoma by fine-needle aspiration biopsy: a cytomorphologic and immunophenotypic approach. Diagn Cytopathol 23:375-379
17. Lewis RE, Cruse JM, Sanders CM, Webb RN, Tillman BF, Beason KL, Lam J, Koehler J (2006) The immunophenotype of pre-TALL/LBL revisited. Exp Mol Pathol 81:162-165
18. Merchant SH, Amin MB, Viswanatha DS (2006) Morphologic and immunophenotypic analysis of angioimmunoblastic T-cell lymphoma: emphasis on phenotypic aberrancies for early diagnosis. Am J Clin Pathol 126:29-38
19. Chen W, Kesler MV, Karandikar NJ, McKenna RW, Kroft SH (2006) Flow cytometric features of angioimmunoblastic T-cell lymphoma. Cytometry B Clin Cytom 70:142-148
20. Juco J, Holden JT, Mann KP, Kelley LG, Li S (2003) Immunophenotypic analysis of anaplastic large cell lymphoma by flow cytometry. Am J Clin Pathol 119:205-212
21. Whittaker SJ, Foss FM (2007) Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma. Cancer Treat Rev 33:146-160
22. Dearden C (2007) Is there a role for hemopoietic stem-cell transplantation in CTCL? Oncology (Williston Park) 21:24-28
23. Rezania D, Cualing HD, Ayala E (2007) The diagnosis, management, and role of hematopoietic stem cell transplantation in aggressive peripheral T-cell neoplasms. Cancer Control 14:151-159
24. Yokoyama H, Yamada MF, Ishizawa K, Yamamoto J, Tomiya Y, Harigae H, Kameoka J, Ichinohasama R, Sasaki T (2007) Successful treatment of advanced extranodal NK/T cell lymphoma with unrelated cord blood transplantation. Tohoku J Exp Med 211:395-399
25. Frankel AE, Laver JH, Willingham MC, Burns LJ, Kersey JH, Vallera DA (1997) Therapy of patients with T-cell lymphomas and leukemias using an anti-CD7 monoclonal antibody-ricin A chain immunotoxin. Leuk Lymphoma 26:287-298
26. Uckun FM, Bellomy K, O'Neill K, Messinger Y, Johnson T, Chen CL (1999) Toxicity, biological activity, and pharmacokinetics of TXU (anti-CD7)-pokeweed antiviral protein in chimpanzees and adult patients infected with human immunodeficiency virus. J Pharmacol Exp Ther 291:1301-1307
27. van Oosterhout YV, van Emst L, Schattenberg AV, Tax WJ, Ruiter DJ, Spits H, Nagengast FM, Masereeuw R, Evers S, de Witte T, Preijers FW (2000) A combination of anti-CD3 and anti-CD7 ricin A-immunotoxins for the in vivo treatment of acute graft versus host disease. Blood 95:3693-3701
28. Olsen E, Duvic M, Frankel A, Kim Y, Martin A, Vonderheid E, Jegasothy B, Wood G, Gordon M, Heald P, Oseroff A, Pinter-Brown L, Bowen G, Kuzel T, Fivenson D, Foss F, Glode M, Molina A, Knobler E, Stewart S, Cooper K, Stevens S, Craig F, Reuben J, Bacha P, Nichols J (2001) Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 19:376-388
29. Foss F (2006) Clinical experience with denileukin diftitox (ONTAK). Semin Oncol 33:S11-16
30. Neville DM, Scharff J, Srinivasachar K (1992) In vivo T-cell ablation by a holo-immunotoxin directed at human CD3. Proc Natl Acad Sci USA 89:2585-2589
31. Hu H, Stavrou S, Cairns Baker B, Tornatore C, Scharff J, Okunieff P, Neville DM Jr (1997) Depletion of T lymphocytes with immunotoxin retards the progress of experimental allergic encephalomyelitis in rhesus monkeys. Cell Immunol 177:26-34
32. Vallera DA, Carroll SF, Brief S, Blazar BR (1992) Anti-CD3 immunotoxin prevents low-dose STZ/interferon-induced autoimmune diabetes in mouse. Diabetes 41:457-464
33. Thomas JM, Contreras JL, Smyth CA, Lobashevsky A, Jenkins S, Hubbard WJ, Eckhoff DE, Stavrou S, Neville DM Jr, Thomas FT (2001) Successful reversal of streptozotocin-induced diabetes with stable allogeneic islet function in a preclinical model of type 1 diabetes. Diabetes 50:1227-1236
34. Rigaut KD, DeMonte L, Scharff JE, Pieber EP, Neville DM, Malavasi F (1996) Bispecific anti-CD3/CD4-CRM9: A novel bifunctional immunotoxin targeting CD3+CD4+ T cells. Tumor Target 2:76-84
35. Liu YY, Gordienko I, Mathias A, Ma S, Thompson J, Woo JH, Neville DM Jr (2000) Expression of an anti-CD3 single-chain immunotoxin with a truncated diphtheria toxin in a mutant CHO cell line. Protein Expr Purif 19:304-311
36. Thompson J, Stavrou S, Weetall M, Hexham JM, Digan ME, Wang Z, Woo JH, Yu Y, Mathias A, Liu YY, Ma S, Gordienko I, Lake P, Neville DM Jr (2001) Improved binding of a bivalent single-chain immunotoxin results in increased efficacy for in vivo T-cell depletion. Protein Eng 14:1035-1041
37. Woo JH, Liu YY, Mathias A, Stavrou S, Wang Z, Thompson J, Neville DM Jr (2002) Gene optimization is necessary to express a bivalent anti-human anti-T cell immunotoxin in Pichia pastoris. Protein Expr Purif 25:270-282
38. Woo JH, Neville DM Jr (2003) Separation of bivalent anti-T cell immunotoxin from Pichia pastoris glycoproteins by borate anion exchange. Biotechniques 35:392-398
39. Woo JH, Liu YY, Stavrou S, Neville DM Jr (2004) Increasing secretion of a bivalent anti-T-cell immunotoxin by Pichia pastoris. Appl Environ Microbiol 70:3370-3376
40. Woo JH, Liu YY, Neville DM Jr (2006) Minimization of aggregation of secreted bivalent anti-human T cell immunotoxin in Pichia pastoris bioreactor culture by optimizing culture conditions for protein secretion. J Biotechnol 121:75-85
41. Woo JH, Liu J, Kang SH, Singh R, Park SK, Su Y, Ortiz J, Neville DM, Willingham MC, Frankel AE (2007) GMP production and characterization of the bivalent anti-human T cell immunotoxin, A-dmDT390-bisFv(UCHT1) for phase I/II clinical trials. Protein Expr Purif doi: 10.1016/j.pep.2007.11.006
42. Hertler AA, Spitler LE, Frankel AE (1987) Humoral immune response to a ricin A chain immunotoxin in patients with metastatic melanoma. Cancer Drug Deliv 4:245-253
43. Hertler AA, Schlossman DM, Borowitz MJ, Poplack DG, Frankel AE (1989) An immunotoxin for the treatment of T-acute lymphoblastic leukemic meningitis: studies in rhesus monkeys. Cancer Immunol Immunother 28:59-66
44. Cantrell DA, Davies AA, Crumpton MJ (1985) Activators of protein kinase C down-regulate and phosphorylate the T3/T-cell antigen receptor complex of human T lymphocytes. Proc Natl Acad Sci USA 82:8158-8162
45. Sarmiento UM, Riley JH, Knaack PA, Lipman JM, Becker JM, Gately MK, Chizzonite R, Anderson TD (1994) Biologic effects of recombinant human interleukin-12 in squirrel monkeys (Sciureus saimiri). Lab Invest 71:862-873
46. Cohen KA, Liu TF, Cline JM, Wagner JD, Hall PD, Frankel AE (2004) Toxicology and pharmacokinetics of DT388IL3, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human interleukin 3 (IL3), in cynomolgus monkeys. Leuk Lymphoma 45:1647-56
47. Cohen KA, Liu T, Bissonette R, Puri RK, Frankel AE (2003) DAB389EGF fusion protein therapy of refractory glioblastoma multiforme. Curr Pharm Biotechnol 4:39-49
48. Hotchkiss CE, Hall PD, Cline JM, Willingham MC, Kreitman RJ, Gardin J, Latimer A, Ramage J, Feely T, DeLatte S, Tagge EP, Frankel AE (1999) Toxicology and pharmacokinetics of DTGM, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human granulocyte-macrophage colony-stimulating factor, in cynomolgus monkeys. Toxicol Appl Pharmacol 158:152-160
49. Frankel AE, Powell BL, Hall PD, Case LD, Kreitman RJ (2002) Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia. Clin Cancer Res 8:1004-1013
50. Frankel AE, Fleming DR, Hall PD, Powell BL, Black JH, Leftwich C, Gartenhaus R (2003) A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia. Clin Cancer Res 9:3555-3561
51. Frankel AE, Liu J, Rizzieri DA, Hogge DE (2007) Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia. Leuk Lymphoma doi: 10.1080/10428190701799035
52. Foss FM, Borkowski TA, Gilliom M, Stetler-Stevenson M, Jaffe ES, Figg WD, Tompkins A, Bastian A, Nylen P, Woodworth T et al (1994) Chimeric fusion protein toxin DAB486IL-2 in advanced mycosis fungoides and the Sezary syndrome: correlation of activity and interleukin-2 receptor expression in a phase II study. Blood 84:1765-1774
53. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N (2006) Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355:1018-1028
54. Ma S, Thompson J, Hu H, Neville Jr DM (1996) Expression and characterization of a divalent chimeric anti-human CD3 single chain antibody. Scand J Immunol 43:134-139